---
title: "Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292761561.md"
description: "Acumen Pharmaceuticals (NASDAQ: ABOS) presented data on its Enhanced Brain Delivery™ program at AAIC 2026, highlighting improved anti-AβO antibody brain penetration in preclinical models. The company also shared insights from the ALTITUDE-AD trial involving early symptomatic Alzheimer’s patients, marking significant progress in developing treatments targeting soluble amyloid beta oligomers."
datetime: "2026-07-15T11:32:46.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292761561.md)
  - [en](https://longbridge.com/en/news/292761561.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292761561.md)
generator: "portal-rs"
---

# Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ (EBD™) Program Data and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company traded on NASDAQ as ABOS, shared groundbreaking updates at the Alzheimer's Association International Conference 2026 in London. Collaborating with JCR Pharmaceuticals, studies revealed enhanced brain penetration of anti-AβO antibodies in mouse and non-human primate models. These developments aim to target soluble amyloid beta oligomers for Alzheimer’s disease treatment. Moreover, research involving early symptomatic AD patients shed light on the experiences of participants in the ALTITUDE-AD trial and their study partners. This signifies a significant advancement in the ongoing fight against Alzheimer's, showcasing promising strides in the field.

### Related Stocks

- [ABOS.US](https://longbridge.com/en/quote/ABOS.US.md)
- [4552.JP](https://longbridge.com/en/quote/4552.JP.md)

## Related News & Research

- [BlackRock Inc. Makes New Investment in Acumen Pharmaceuticals, Inc. $ABOS](https://longbridge.com/en/news/298099843.md)
- [Acumen Pharmaceuticals to present Enhanced Brain Delivery Alzheimer’s data at AAIC 2026](https://longbridge.com/en/news/291924791.md)
- [BrainsWay says pilot study shows 83.3% response rate for Deep TMS in depression with early-stage Alzheimer’s](https://longbridge.com/en/news/298310913.md)
- [Acumen Pharmaceuticals to present at Cantor Global Healthcare Conference fireside chat](https://longbridge.com/en/news/297822980.md)
- [Annovis Bio Targets March 2027 Alzheimer’s Readout, Prepares Rolling NDA](https://longbridge.com/en/news/297849508.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**